ArticleGeroScience2026
Spatiotemporal profiling of white matter lesions and their contribution in the pathologies of Parkinson's disease animal models.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Increasing evidence has identified significant white matter lesions (WMLs) in Parkinson's disease (PD) patients. However, the complex relationships between WMLs and the neuropathological changes of PD remain unclear. In this study, we comprehensively elucidated the spatiotemporal dynamics of WMLs in rotenone-, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD models, and α-synuclein (α-Syn) (A53T) transgenic mice. The results showed that WMLs occurred across multiple brain regions and gradually aggravated as PD models progressed. Notably, WMLs emerged as early pathological events of PD prior to dopaminergic neuronal loss. Consistently, WMLs-related axial movement disorders, including gait and balance impairments, preceded those caused by nigrostriatal injury. Further in vitro studies revealed that oligodendrocyte precursor cells (OPCs) dysfunction caused by 1-methyl-4-phenylpyridinium (MPP⁺) or α-Syn could induce dopaminergic axonal breakage and neuronal damage, confirming myelination disorder promoted dopaminergic neuronal degeneration. This finding was certified in additional in vivo studies using lysophosphatidylcholine (LPC)-induced demyelination models. The results validated that WMLs could independently induce dopaminergic neuronal damage and nigrostriatal pathway-related movement disorders. Moreover, comorbid WMLs in PD mice further aggravated this process. In summary, our findings uncovered the spatiotemporal characteristics of WMLs and their contribution to PD pathological development, highlighting that targeting WMLs might be a potential strategy for PD intervention.
Indexed as
Identifiers
42397532What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.